Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Alvotech Resolves Patent, Trade Secret Disputes With AbbVie

March 8, 2022, 10:13 PM

Alvotech secures U.S. rights for its proposed Humira biosimilar.

  • Expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
  • All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including the ITC action brought forth in December
  • NOTE: Dec. 7, Alvotech Going Public Through Oaktree SPAC Merger

NOTE

  • AbbVie Inc. rose 0.0% in postmarket trading to $147.19 as of 5:10 p.m. New York time
    • The average 12-month price target of $152.55 is 3.6% above the current price
    • 18 buys, 7 holds, 1 sells

To view the source of this information, click here ...